Reaction

Blepharitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,896 reports · 86 co-occurring drugs

As of the last recalculation, Blepharitis appears in 3,896 FAERS reports alongside 86 co-occurring drug terms. The strongest observed disproportionality signal is DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE (PRR 33.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dorzolamide Hydrochloride And Timolol Maleate	49	33.5	33.7
Bimatoprost	141	27.1	27.2
Travoprost	35	21.8	21.9
Brimonidine Tartrate	57	17.3	17.4
Lifitegrast	51	16.9	16.9
Carboxymethylcellulose Sodium	29	16.6	16.7
Dupilumab	923	13.1	13.1
Panitumumab	37	12.7	12.8
Cenegermin-Bkbj	28	12.5	12.5
Latanoprost	99	10.8	10.8
Erlotinib	19	10.5	10.5
Timolol Maleate	19	10.3	10.3
Prednisolone Acetate	19	9.9	9.9
Brinzolamide	15	9.3	9.3
Erythromycin	32	9.2	9.2
Timolol	20	8.9	8.9
Erlotinib Hydrochloride	20	8.6	8.6
Ranibizumab	38	7.7	7.7
Chlorhexidine Gluconate	13	7.6	7.6
Mometasone	24	7.0	7.0
Quinine	11	6.9	6.9
Cetirizine Hcl	11	6.4	6.4
Moxifloxacin Hydrochloride	24	6.4	6.4
Crisaborole	11	6.1	6.1
Cyclosporine	117	5.8	5.8
Bortezomib	94	5.7	5.7
Clobetasol Propionate Ointment Usp, 0.05%	11	5.7	5.7
Clobetasol Propionate	11	5.7	5.7
Aflibercept	32	5.5	5.5
Cetuximab	32	5.5	5.5
Triamcinolone Acetonide Ointment Usp, 0.05%	23	5.3	5.3
Hyoscyamine Sulfate	9	5.2	5.3
Azelastine	16	4.8	4.8
Tolterodine Tartrate	8	4.8	4.8
Doxyclycline Hyclate	15	4.7	4.7
Granisetron Hydrochloride	9	4.6	4.6
Granisetron	9	4.6	4.6
Moxifloxacin	12	4.6	4.6
Infliximab-Dyyb	24	4.4	4.4
Triamcinolone Acetonide	25	4.3	4.3
Methimazole	6	4.1	4.1
Tobramycin Solution	9	4.0	4.0
Thalidomide	27	3.9	4.0
Tobramycin Sulfate	9	3.9	3.9
Botulinum Toxin Type A	9	3.9	3.9
Isotretinoin	35	3.8	3.8
Paroxetine Hydrochloride Hemihydrate	23	3.7	3.7
Liothyronine Sodium	6	3.7	3.7
Paroxetine	23	3.6	3.6
Vemurafenib	8	3.6	3.6
Gefitinib	6	3.6	3.6
Amlodipine Besylate And Benazepril Hydrochloride	6	3.5	3.5
Trastuzumab	43	3.4	3.4
Pertuzumab	17	3.4	3.4
Dutasteride	5	3.3	3.3
Pravastatin Sodium	12	3.2	3.2
Docetaxel Anhydrous	40	3.2	3.2
Docetaxel	40	3.2	3.2
Tobramycin	14	3.1	3.1
Fosaprepitant Dimeglumine	8	3.1	3.1
Terbinafine Hydrochloride	5	3.0	3.0
Elexacaftor, Tezacaftor, And Ivacaftor	7	3.0	3.0
Levocetirizine Dihydrochloride	13	2.9	2.9
Lisinopril And Hydrochlorothiazide Tablets	4	2.7	2.7
Fexofenadine Hydrochloride	11	2.7	2.7
Paclitaxel (Aibumin-Bound)	41	2.7	2.7
Aprepitant	9	2.6	2.6
Trametinib	11	2.4	2.4
Fluorouracil	35	2.4	2.4
Fluorouracil Cream, 0.5%	34	2.4	2.4
Paclitaxel	42	2.3	2.3
Obinutuzumab	7	2.3	2.3
Bimekizumab	9	2.3	2.3
Dofetilide	4	2.0	2.0
Ivacaftor	3	2.0	2.0
Fremanezumab-Vfrm	4	1.9	1.9
Onabotulinumtoxina	26	1.8	1.8
Carfilzomib	9	1.7	1.7
Irinotecan Hydrochloride	4	1.7	1.7
Certolizumab Pegol	34	1.6	1.6
Ixekizumab	9	1.3	1.3
Guselkumab	8	1.2	1.2
Ixazomib	6	1.1	1.1
Osimertinib	6	1.0	1.0
Pegfilgrastim	17	0.9	0.9
Adapalene	10	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.